Results 111 to 120 of about 71,439 (210)

Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

BMC Cancer, 2010
Background Stereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported previously. Case Presentation
Chen Chien-An, Hsieh Yen-Ping, Wang Li-Ying, Chen Yu-Jen, Lin Shih-Chiang, Chang Hou-Tai, Hsieh Chen-Hsi, Chong Ngot-Swan, Lin Shoei, Chen Chun-Yi, Shueng Pei-Wei   +10 more
doaj   +1 more source

Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung Cancer [PDF]

, 2018
Non-small cell lung cancer (NSCLC) is currently the number one cause of cancer death in the United States for both men and women.1 Mutations in the epidermal growth factor receptor (EGFR) gene are detected in approximately 30% of individuals with ...
Omerza, PhD, Gregory, Schoenberg, Benjamen   +1 more
core   +1 more source

Four Cases of Interstitial Lung Disease Induced by Erlotinib 
and A Review of the Literatures

Chinese Journal of Lung Cancer, 2012
Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors which are used for non-small cell lung cancer. Although this class of agents is considered to be relatively safe, the most serious, but rare, adverse ...
Xiaoling WU, Guanghui GAO, Shengxiang REN, Caicun ZHOU   +3 more
doaj   +1 more source

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective Erlotinib has been approved worldwide for second- and third-line treatment of advanced NSCLC. Clinical trials showed that patients with EGFR mutations treated with erlotinib has better clinical outcomes.
Li MA, Ting WANG
doaj  

Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD

Frontiers in Immunology
IntroductionErlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, interact with amyloid β (Aβ), raising the possibility that ...
Hyun-ju Lee, Hyun-ju Lee, Jeong-Woo Hwang, Jeong-Woo Hwang, Jieun Kim, A-Ran Jo, A-Ran Jo, Jin-Hee Park, Yoo Joo Jeong, Yoo Joo Jeong, Yoo Joo Jeong, Ji-Yeong Jang, Ji-Yeong Jang, Ji-Yeong Jang, Su-Jeong Kim, Jeong-Heon Song, Hyang-Sook Hoe, Hyang-Sook Hoe, Hyang-Sook Hoe   +18 more
doaj   +1 more source

EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. [PDF]

, 2013
Understanding tumor-induced angiogenesis is a challenging problem with important consequences for the diagnosis and treatment of cancer. In this study, we define a novel function for epithelial membrane protein-2 (EMP2) in the control of angiogenesis ...
Braun, J, Chan, A, Dhawan, P, Fu, M, Goodglick, L, Gordon, LK, Kiyohara, M, Wadehra, M   +7 more
core  

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects [PDF]

, 2017
Diamond, Michael S, et al,, Govero, Jennifer   +2 more
core   +2 more sources

Erlotinib in the trentment of Advanced Non-small-cell Lung Cancer: A Systematic Review

Chinese Journal of Lung Cancer, 2009
Background and objective Erlotinib is a new and efficient anti-tumor targeted therapy drug, and it has been used in China for non-small cell lung cancer since 2006. The aim of this study is to review the effectiveness and safety of erlotinib for treating
Yanming TANG, Shiyong WANG, Zhenjun YANG, Lina ZHU   +3 more
doaj  

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy [PDF]

, 2008
Abderrahim Fandi, AP Meert, AS Merseburger, D Veale, DA Eberhard, David H. Johnson, DC Spaulding, DJ Slamon, DS Salomon, DW Bell, F Cappuzzo, F Cappuzzo, FA Shepherd, FR Hirsch, G Giaccone, Giuseppe Giaccone, International Conference on Harmonisation, J Brabender, J Gawrychowski, JG Paez, JP Kallio, JR Woodburn, Judith S. Ochs, L Bingle, M Volm, M-S Tsao, Mette Janas, N Thatcher, R Sordella, Renee B. Iacona, RI Nicholson, Roy S. Herbst, RS Herbst, RS Herbst, SJ Pocock, TJ Lynch, U Gatzemeier, Y Nakayama, Y Ohsaki   +38 more
core   +1 more source

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]

, 2017
et al,, Ghasemi, Reza
core   +2 more sources